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Combined hepatocellular-cholangiocarcinoma (CHC) is a rare type of primary 
liver cancer. Due to its complex histopathological characteristics, the imaging 
features of CHC can overlap with those of hepatocellular carcinoma (HCC) and 
intrahepatic cholangiocarcinoma (ICC).
AIM 
To investigate the possibility and efficacy of differentiating CHC from HCC and 
ICC by using contrast-enhanced ultrasound (CEUS) Liver Imaging Reporting and 
Data System (LI-RADS) and tumor biomarkers.
METHODS 
Between January 2016 and December 2019, patients with histologically confirmed 
CHC, ICC and HCC with chronic liver disease were enrolled. The diagnostic 
formula for CHC was as follows: (1) LR-5 or LR-M with elevated alpha-
fetoprotein (AFP) and carbohydrate antigen 19-9 (CA19-9); (2) LR-M with 
elevated AFP and normal CA19-9; or (3) LR-5 with elevated CA19-9 and normal 
AFP. The sensitivity, specificity, accuracy and area under the receiver operating 
characteristic curve were calculated to determine the diagnostic value of the 
criteria.
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RESULTS 
After propensity score matching, 134 patients (mean age of 51.4 ± 9.4 years, 108 
men) were enrolled, including 35 CHC, 29 ICC and 70 HCC patients. Based on 
CEUS LI-RADS classification, 74.3% (26/35) and 25.7% (9/35) of CHC lesions 
were assessed as LR-M and LR-5, respectively. The rates of elevated AFP and 
CA19-9 in CHC patients were 51.4% and 11.4%, respectively, and simultaneous 
elevations of AFP and CA19-9 were found in 8.6% (3/35) of CHC patients. The 
sensitivity, specificity, positive predictive value, negative predictive value, 
accuracy and area under the receiver operating characteristic curve of the 
aforementioned diagnostic criteria for discriminating CHC from HCC and ICC 
were 40.0%, 89.9%, 58.3%, 80.9%, 76.9% and 0.649, respectively. When considering 
the reported prevalence of CHC (0.4%-14.2%), the positive predictive value and 
NPV were revised to 1.6%-39.6% and 90.1%-99.7%, respectively.
CONCLUSION 
CHCs are more likely to be classified as LR-M than LR-5 by CEUS LI-RADS. The 
combination of the CEUS LI-RADS classification with serum tumor markers 
shows high specificity but low sensitivity for the diagnosis of CHC. Moreover, 
CHC could be confidently excluded with high NPV.
Key Words: Combined hepatocellular-cholangiocarcinoma; Contrast-enhanced ultrasound; 
Liver imaging reporting and data system; Sensitivity; Diagnosis; Liver neoplasms
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Core Tip: The imaging features of combined hepatocellular-cholangiocarcinoma (CHC) 
are complicated due to its complex histopathological characteristics. In addition, 
biopsy may misguide the correct diagnosis of CHC due to sampling error or tissue 
insufficiency. This study investigated the diagnostic value of the contrast-enhanced 
ultrasound Liver Imaging Reporting and Data System classification in association with 
serological tumor markers in differentiating CHC from hepatocellular carcinoma and 
intrahepatic cholangiocarcinoma. The results showed that the combined diagnostic 
criteria had high specificity and negative predictive value but low sensitivity for the 
diagnosis of CHC. These findings could help radiologists and clinical investigators 
confidently exclude CHC lesions in the clinical setting.
Citation: Yang J, Zhang YH, Li JW, Shi YY, Huang JY, Luo Y, Liu JB, Lu Q. Contrast-
enhanced ultrasound in association with serum biomarkers for differentiating combined 
hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic 




Combined hepatocellular-cholangiocarcinoma (CHC) is increasingly recognized in 
cirrhotic liver, with a reported prevalence of 0.4%-14.2% of all primary liver 
carcinomas[1-3]. CHC is the second most common primary liver cancer in cirrhotic liver, 
followed by intrahepatic cholangiocarcinoma (ICC), excluding perihilar 
cholangiocarcinoma[4]. According to the 2010 World Health Organization classifica-
tion[5], this special type of tumor requires the presence of both unambiguously 
differentiated hepatocellular and biliary components. CHC can have various imaging 
features overlapping with hepatocellular carcinoma (HCC), ICC and liver metastasis 
for complex histopathological components[6-8]. However, the prognosis and treatment 
of CHC differ from those of HCC and ICC[9], and therefore the accurate diagnosis of 
this tumor type is of great importance for appropriate patient management.
A few studies have reported the imaging features of CHC lesions on contrast-
enhanced ultrasound (CEUS)[10-13]. Theoretically, due to the mixed elements of CHC, 
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both HCC-like and ICC-like imaging features would be visualized. In addition, serum 
biomarkers, especially alpha-fetoprotein (AFP) and carbohydrate antigen 19-9 (CA19-
9), have been shown to be helpful in the diagnosis of CHC[10,11,13,14]. The combination of 
CEUS and serum biomarkers was reported to improve specificity for the 
differentiation between CHC and HCC or ICC in a study population not limited to 
patients at risk for HCC[10].
The American College of Radiology released CEUS Liver Imaging Reporting and 
Data System (LI-RADS) for standardizing CEUS diagnosis of liver nodules in high-risk 
patients[15]. Although not fully validated, CEUS LI-RADS has been reported to be 
effective for the diagnosis of HCC[16,17]. However, challenges still exist for the 
differential diagnosis of highly suspicious HCC and other malignant entities, such as 
CHC and ICC. The purpose of this study was to investigate whether the combination 
of CEUS LI-RADS and serum biomarkers is helpful for differentiating CHC from HCC 
and ICC in patients with chronic liver disease.
MATERIALS AND METHODS
Study subjects
This retrospective study was approved by the institutional review board, and 
informed consent was obtained from all patients. From January 2016 to December 
2019, patients with pathologically confirmed primary liver cancer after liver resection 
were retrospectively selected through a review of our Ultrasonic Information System. 
Inclusion criteria included: (1) CEUS performed within 1 mo before liver resection; (2) 
Patients with risk factors for HCC, including cirrhosis and chronic hepatitis B; and (3) 
Testing of AFP and CA19-9 levels within 7 d before curative resection. Lesions with 
neoplastic vascular thrombi were excluded from this study. Eventually, we included 
35 CHC, 29 ICC and 1051 HCC patients. After one-to-two (CHC:HCC = 1:2) propensity 
score matching by tumor size, age and gender, 70 HCC lesions were selected for 
analysis. A flow chart for the study population selection is presented in Figure 1.
Ultrasound examination
All patients underwent B-mode ultrasound and CEUS examination by an ultrasound 
system (IU22, Philips Medical Solutions; Mountain View, CA, United States) equipped 
with a C5-1 abdominal convex transducer (frequency range of 1-5 MHz). The CEUS 
examination was performed according to technical recommendations following the 
World Federation for Ultrasound in Medicine and Biology-European Federation of 
Societies for Ultrasound in Medicine and Biology guidelines after a conventional 
ultrasound study[18]. After activation of the contrast-specific imaging mode, 1.2-2.4 mL 
of contrast agent (SonoVue, Bracco, Milan, Italy) was injected intravenously and 
flushed with 5 mL of 0.9% saline solution through a 20-gauge angio-catheter needle 
placed in the antecubital vein. The imaging timer was started immediately upon 
completion of SonoVue injection. The set of images was stored on the hard disk of the 
ultrasound system and copied to a portable hard disk for later evaluation.
CEUS imaging analysis
According to the CEUS LI-RADS (2017 version), a hepatic nodule is categorized from 
LR-1 to LR-5 or LR-M and LR-TIV according to the likelihood of HCC[17]. The following 
imaging features were used to categorize each nodule: Nodule size, pattern of arterial 
phase enhancement, presence, timing and degree of washout and tumor-in-vein (
Supplementary Appendix Table 1).
The CEUS images were reviewed independently by two certified radiologists (Li JW 
and Shi YY with more than 5 and 3 years of experience with liver CEUS, respectively) 
who were blinded to the pathology results and serum biomarker levels and assigned a 
category to each nodule according to CEUS LI-RADS (2017 version)[15,17]. In case of 
discordant interpretations between the reviewers, arbitration from an expert 
radiologist with more than 10 years of experience (Lu Q) was performed.
Diagnostic criteria for distinguishing CHC from HCC or ICC
The diagnostic criteria of CHC were defined as follows: (1) LR-5 or LR-M lesion with 
simultaneously elevated AFP and CA19-9 (AFP > 20 ng/mL and CA19-9 > 100 
units/mL) levels[19-21]; (2) LR-M lesion with elevated AFP levels and normal CA19-9 
Levels; or (3) LR-5 lesion with elevated CA19-9 levels and normal AFP levels. The 
diagnostic test was performed with pathological results as the reference standard.
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Figure 1 Study population selection flowchart. AFP: Alpha-fetoprotein; CA19-9: Carbohydrate antigen 19-9; CEUS: Contrast-enhanced ultrasound; CHC: 
Combined hepatocellular-cholangiocarcinoma; HCC: Hepatocellular carcinoma; ICC: Intrahepatic cholangiocarcinoma.
Statistical analysis
Quantitative data were expressed as the mean ± standard deviation. Qualitative data 
were presented as numbers and percentages. Differences in quantitative variables 
were tested by the independent sample t-test. Comparison of the rates of imaging 
characteristics was performed by using the χ2 test or Fisher’s exact test. The area under 
the receiver operating characteristic curve (AUC) was used to analyze the performance 
of the diagnostic criteria. The sensitivity, specificity, accuracy, positive predictive 
value (PPV) and negative predictive value (NPV) for CHC were calculated by using 
standard procedures[22].
Kappa values were evaluated to measure intrareader agreement of CEUS features 
and CEUS LI-RADS classification of the nodules. The strength of agreement was 
interpreted according to the classification scales for kappa: 0.00-0.20 poor, 0.21-0.40 
fair, 0.41-0.60 moderate, 0.61-0.80 substantial and 0.81-1.00 almost perfect[23]. 
Propensity score matching was performed with R software version 3.6.1 (R Foundation 
for Statistical Computing, Vienna, Austria; www.r-project.org). Statistical analyses 
were performed with the statistical software package SPSS, version 25.0; IBM, 
Armonk, NY, United States). Significance was defined as two-sided P < 0.05.
RESULTS
Patient characteristics
After propensity score matching, a total of 35 CHC, 29 ICC and 70 HCC patients were 
included for analysis. The clinical characteristics of the 134 patients are shown in 
Table 1. In the CHC group, the mean nodule size was 5.6 ± 3.7 cm (range 2.0-17.0 cm) 
in diameter. Elevated AFP levels were found in 51.4% (18/35) of CHC patients, in 
contrast to 10.3% (3/29) of ICC patients and 58.6% (41/70) of HCC patients (P = 0.001 
and 0.535, respectively). In addition, elevated CA19-9 levels were found in 11.4% 
(4/35) of CHC patients compared with 31.0% (9/29) of ICC patients and 1.4% (1/70) of 
HCC patients (P = 0.066 and 0.041, respectively). Simultaneous elevations in AFP and 
CA19-9 were found in 8.6% (3/35) of CHC, 3.4% (1/29) of ICC and 1.4% (1/70) of 
HCC patients (P > 0.05).
CEUS imaging characteristics
All the CHC lesions illustrated hyperenhancement in the arterial phase and hypo-
enhancement in the portal or late phase. In the arterial phase, peripheral irregular rim-
like and non-rim-like hyperenhancement were demonstrated in 17.1% (6/35) and 
82.9% (29/35) of CHC lesions, respectively. In the portal phase, early washout was 
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Table 1 Baseline characteristics of the study patients with combined hepatocellular-cholangiocarcinoma, intrahepatic 
cholangiocarcinoma and hepatocellular carcinoma
CHC, n = 35 Non-CHC P1 P2
ICC, n = 29 HCC, n = 70
Tumor size in cm 5.6 ± 3.7 6.9 ± 3.3 5.1 ± 3.1 0.158 0.432
Age in yr 49.3 ± 9.5 55.0 ± 9.3 50.5 ± 9.2 0.018 0.555
Numbers of male 31 (88.6) 24 (82.8) 46 (76.7) 0.720
HBV (+) 30 (85.7) 21 (72.4) 62 (88.6) 0.224 0.756
HCV (+) 3 (8.6) 3 (10.3) 0 (0.0) 1.000 0.035
Liver cirrhosis 23 (65.7) 12 (41.4) 42 (60.0) 0.077 0.671
AFP, > 20 ng/mL 18 (51.4) 3 (10.3) 41 (58.6) 0.001 0.535
CA19-9, > 100 U/mL 4 (11.4) 9 (31.0) 1 (1.4) 0.066 0.041
AC 3 (8.6) 1 (3.4) 1 (1.4) 0.620 0.107
Data are numbers of lesions, with percentages in parentheses or mean ± SD. P1 statistical difference between combined hepatocellular-cholangiocarcinoma 
(CHC) and intrahepatic cholangiocarcinoma (ICC). P2 statistical difference between CHC and hepatocellular carcinoma (HCC). AC means simultaneous 
elevated alpha-fetoprotein (AFP) and carbohydrate antigen 19-9 levels (CA19-9).
present in 74.3% (26/35) of CHC lesions compared with 96.6% (28/29) of ICC lesions (
P = 0.017) and 18.6% (13/70) of HCC patients (P < 0.001). Marked washout within 120 
s was found in 5.7% (2/35) of CHC lesions, in contrast to 3.4% (1/29) of ICC lesions (P 
= 1.000) and none of the HCC lesions (P = 0.109). According to CEUS LI-RADS, 25.7% 
(9/35) and 74.3% (26/35) of CHCs were classified as LR-5 and LR-M, respectively, in 
contrast to none and 100% in ICC (P = 0.003) and 81.4% (57/70) and 18.6% (13/70) in 
HCC (P < 0.001). The pre-contrast and contrast-enhanced ultrasonographic imaging 
features are presented in Table 2.
The interobserver agreement of CEUS features for the CHC and non-CHC groups is 
summarized in Table 3. In the CHC group, the k values of interobserver agreements on 
the arterial phase hyperenhancement pattern, early washout and marked washout 
were 0.624, 0.608 and 0.635, respectively. In the non-CHC group, the k values of 
interobserver agreements on arterial enhancement pattern, early washout and marked 
washout were 0.524, 0.875 and 0.662, respectively. The k values of CEUS LI-RADS 
categorization in the two groups were 0.663 and 0.876, respectively.
Performance of CHC diagnostic criteria in distinguishing between CHC and HCC or 
ICC
Serum tumor biomarkers (AFP and CA19-9) and the CEUS LI-RADS categorization of 
the 134 patients are shown in Table 4 (Figure 2-4). Table 5 shows the performance of 
the diagnostic criteria. The AUC, sensitivity, specificity, PPV, NPV, and accuracy were 
0.649, 40.0%, 89.9%, 58.3%, 80.9% and 76.9%, respectively. In this study, CHC 
accounted for 26.1% (35/134) of the study population, yielding an adjusted PPV 
of 58.3% and NPV of 80.9%. However, the actual prevalence of CHC is much lower, 
reportedly accounting for 0.4%-14.2% of primary hepatic cancers[2,24,25]. Considering 
eighth reported prevalence of CHC (0.4%-14.2%), the PPV and NPV were modified to 
1.6%-39.6% and 90.1%-99.7%, respectively.
DISCUSSION
CHC is the second most common type of primary liver cancer in cirrhotic liver[4]. A 
definitive diagnosis of CHC requires both unambiguously differentiated 
hepatocellular and biliary components in the same tumor in pathological analysis as 
per the World Health Organization classification[5]. However, biopsy may misguide 
the correct diagnosis of CHC due to sampling error or tissue insufficiency[26,27], which 
highlights the importance of surgical specimens and imaging diagnosis. Our study 
indicated that a higher percentage of CHC was classified as LR-M than LR-5 (74.3% vs 
25.7%, P < 0.05). Simultaneous elevation of AFP and CA19-9 was present in only 8.6% 
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Table 2 Imaging characteristics of the study patients with combined hepatocellular-cholangiocarcinoma and those with intrahepatic 
cholangiocarcinoma and hepatocellular carcinoma, n (%)
CHC, n = 35 Non-CHC P1 P2
ICC, n = 29 HCC, n = 70
Echogenic degree 0.692 0.099
Hypo- 32 (91.4) 25 (86.2) 55 (78.6)
Hyper- 3 (8.6) 4 (13.8) 15 (21.4)
Poor boundary 23 (65.7) 22 (75.9) 36 (51.4) 0.422 0.212
Irregular shape 23 (65.7) 20 (69.0) 30 (42.9) 1.000 0.038
APHE pattern 0.757 0.001
Rim-like 6 (17.1) 6 (20.7) 0 (0.0)
Non-rim-like 29 (82.9) 23 (79.3) 70 (100)
Timing of washout onset 0.017 < 0.001
Early, < 60 s 26 (74.3) 28 (96.6) 13 (18.6)
Late, > 60 s 9 (25.7) 1 (3.4) 57 (81.4)
Degree of washout 1.000 0.109
Marked, as observed within first 
120 s
2 (5.7) 1 (3.4) 0 (0.0)
Mild 33 (94.3) 28 (96.6) 70 (100.0)
CEUS LI-RADS 0.003 < 0.001
LR-5 9 (25.7) 0 (0.0) 57 (81.4)
LR-M 26 (74.3) 29 (100.0) 13 (18.6)
P1 significant difference between combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma. P2 significant difference between 
combined hepatocellular-cholangiocarcinoma and hepatocellular carcinoma. APHE: Arterial phase hyperenhancement; CHC: Combined hepatocellular-
cholangiocarcinoma; HCC: Hepatocellular carcinoma; ICC: Intrahepatic cholangiocarcinoma; LI-RADS: Liver Image Reporting and Data System.
(3/35) of CHC patients. The combination of CEUS LI-RADS and serum AFP and 
CA19-9 levels showed a specificity of 89.9% and accuracy of 76.9% for the diagnosis of 
CHC in patients with chronic liver disease.
In our study, all CHC lesions showed typical manifestations of liver cancer (i.e. the 
enhancement mode of “rapid wash in and out”)[10-12,28]. However, 74.3% (26/35) of CHC 
cases were assessed as LR-M, which is higher than the rates reported by Choi et al[29] 
(28.0%) and Jeon et al[30] (61.4%) based on magnetic resonance imaging (MRI) LI-RADS. 
This discrepancy may be explained by the fact that early washout is more easily 
observed by CEUS due to higher temporal resolution than MRI. In this study, the other 
25.7% (9/35) of CHC lesions were classified as LR-5. In other words, 100% of CHC 
lesions were correctly classified as malignant by CEUS LI-RADS, which is in line with 
the findings of Sagrini et al[12], where CEUS correctly suggested a condition of 
malignancy in a higher number of cases than CT and MRI for the diagnosis of CHC.
Elevated AFP and CA19-9 levels have been reported as potential diagnostic 
indicators for HCC and ICC, respectively[19,31]. Prior studies have demonstrated that the 
combination of AFP and CA19-9 with radiologic characteristics may aid the diagnosis 
of CHC[10,11,13,14]. Huang et al[10] reported that the sensitivity and specificity of diagnosing 
CHC based on their criteria (i.e. simultaneous elevation of AFP and CA19-9 or with a 
tumor marker elevation in discordance with HCC-like or ICC-like pattern on CEUS), 
were 32.5% and 92.8%, respectively, which is comparable to the result of our study. 
Compared with Huang’s study, HCC lesions were selected by propensity score 
matching in this study, which reduced patient selection bias. Moreover, CEUS LI-
RADS was adopted in our criteria, which makes it more standardized to use in the 
clinical setting.
The diagnostic criteria for CHC showed high specificity (89.9%) and modified NPV 
(90.1% to 99.7%), which indicated that CHC could be effectively ruled out by using 
CEUS LI-RADS. Atypical HCC or ICC would be classified as LR-M, a category 
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Table 3 The inter-observer agreement of contrasted-enhanced ultrasound features for the combined hepatocellular-
cholangiocarcinomas and non-combined hepatocellular-cholangiocarcinomas lesions
CHC Non-CHC
Reader 1 Reader 2
K1
Reader 1 Reader 2
K2
APHE pattern 0.624 0.524
Rim-like 6 3 8 3
Non-rim-like 29 32 91 96
Timing of washout onset 0.608 0.875
Early, < 60 s 26 22 42 40
Late, > 60 s 9 13 57 59
Degree of washout 0.635 0.662
Marked, as observed within 
first 120 s
3 3 2 1
Mild 32 32 97 98
CEUS LI-RADS 0.663 0.876
LR-5 9 12 56 58
LR-M 26 23 43 41
Kappa values 0.81-1.0, 0.61-0.80, 0.41-0.60, 0.21-0.40, and 0.00-0.20 correspond to almost perfect, substantial, moderate, fair, and slight, respectively. APHE: 
Arterial Phase Hyperenhancement; CEUS: Contrasted-enhanced ultrasound; CHC: Combined hepatocellular-cholangiocarcinoma; LI-RADS: Liver Imaging 
Reporting and Data system.
Table 4 Contrast-enhanced ultrasound Liver Imaging Reporting and Data System categorization and serum biomarkers of 134 patients
Serum biomarker CHC HCC ICC
LR-5 LR-M LR-5 LR-M LR-5 LR-M
AFP (+) CA19-9 (+) 0 31 0 11 0 11
AFP (-) CA19-9 (-) 5 11 26 5 0 18
AFP (+) CA19-9 (-) 4 111 32 61 0 21
AFP (-) CA19-9 (+) 0 1 0 0 0 8
Total 9 26 58 12 0 29
1Numbers that diagnosis as combined hepatocellular-cholangiocarcinoma (CHC) according to the diagnostic criteria. Alpha-fetoprotein (AFP) (+) = the 
elevated level of AFP (> 20 ng/mL), AFP (-) = the normal level of AFP (≤ 20 ng/mL), carbohydrate antigen 19-9 (CA19-9) (+) = the elevated level of CA19-9 
(> 100 U/mL), CA19-9 (-) = the normal level of CA19-9 (≤ 100 U/mL). HCC: Hepatocellular carcinoma; ICC: Intrahepatic cholangiocarcinoma; LI-RADS: 
Liver Imaging Reporting and Data System.
indicating malignancy but not specific for HCC. Biopsy is recommended for the 
management of LR-M lesions. However, for CHC, the value of biopsy may be limited 
due to sampling error or tissue insufficiency. In such a scenario, combining CEUS LI-
RADS with serum biomarkers could confidently exclude the possibility of CHC if the 
lesion does not meet the criteria. However, the performance of the diagnostic criteria 
in this study indicated that differentiation between CHC and HCC or ICC remains 
challenging.
There are a few limitations to our study. First, this was a single-center retrospective 
case-control study, which may have potential selection bias. Additional multicenter 
prospective studies are needed to validate the diagnostic criteria. Second, the sample 
size was small because of the relatively low incidence of CHC tumors. Third, this 
study mainly enrolled patients with chronic hepatitis B. Therefore, our results may not 
be reproducible in patients with other etiologies, especially liver cirrhosis.
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Table 5 Diagnostic test results and modified positive predictive value and negative predictive value according to reported combined 
hepatocellular-cholangiocarcinoma prevalence
CHC prevalence, % AUC Sensitivity Specificity PPV NPV Accuracy
26.1% (35/134) 0.649 40.0 89.9 58.3 80.9 76.9
0.4%[1,13] 1.6 99.7
14.2%[2,3] 9.6 90.1
AUC: Area under the curve; CHC: Combined hepatocellular-cholangiocarcinoma; NPV: Negative predictive value; PPV: Positive predictive value.
Figure 2 LR-M nodule in a 54-year-old man with chronic hepatitis B. A: A nodule with a diameter of 3.6 cm in the right liver lobe was homogeneously 
hyper-enhanced (arrow) in the arterial phase at contrast-enhanced ultrasound; B: Early washout (53 s) of the contrast agent was observed (arrow); C: Hypo-
enhancement (arrow) in the late phase was shown at contrast-enhanced ultrasonography. Elevated alpha-fetoprotein and normal carbohydrate antigen 19-9 level 
were found by in the serologic data. The nodule was assigned to combined hepatocellular-cholangiocarcinoma lesion according to the diagnostic criteria; D: Both 
hepatocellular carcinoma (orange arrow) and intrahepatic cholangiocarcinoma (yellow arrow) components were found in histopathologic analysis, resulting in a final 
diagnosis of combined hepatocellular-cholangiocarcinoma (hematoxylin and eosin staining; magnification, × 100).
CONCLUSION
In conclusion, CHC could be accurately diagnosed as malignant by CEUS LI-RADS, 
with the majority of the lesions in the LR-M category. The combination of CEUS LI-
RADS classification with serum tumor markers shows high specificity but low 
sensitivity for the diagnosis of CHC. These findings could help radiologists and 
clinical investigators confidently exclude CHC lesions in the clinical setting.
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Figure 3 LR-M nodule in a 55-year-old woman with chronic hepatitis B. A: A hypoechoic nodule with a diameter of 3.4 cm in the left lobe of the liver was 
homogeneously hyper-enhanced (arrow) in the arterial phase; B: Early washout was observed at 32 s after injection of contrast agent (SonoVue; Bracco); C: Hypo-
enhancement of the whole nodule was demonstrated in the late phase. Serologic data indicated normal alpha-fetoprotein and carbohydrate antigen 19-9 levels. The 
nodule was assessed as non-combined hepatocellular-cholangiocarcinoma lesion according to the diagnostic criteria; D: The nodule was proved to be hepatocellular 
carcinoma by pathology (hematoxylin and eosin staining; magnification, × 100).
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Figure 4 LR-M nodule in a 46-year-old man with chronic hepatitis B. A: A hypoechoic nodule with a diameter of 3.9 cm in the right lobe of the liver was 
heterogeneously hyper-enhanced (arrow) in the arterial phase; B: Early washout (30 s) of the contrast agent was observed (arrow); C: Hypo-enhancement of the 
nodule (arrow) in the late phase was shown at contrast-enhanced ultrasound. The patient had both normal alpha-fetoprotein and carbohydrate antigen 19-9 levels. 
The lesion was classified as non-combined hepatocellular-cholangiocarcinoma lesion according to the diagnostic criteria; D: Intrahepatic cholangiocarcinoma and 
cirrhosis of the surrounding liver were confirmed by pathology (hematoxylin and eosin staining; magnification, × 100).
ARTICLE HIGHLIGHTS
Research background
Combined hepatocellular-cholangiocarcinoma (CHC) is a rare type of primary liver 
cancer. Due to its complex histopathological characteristics, the imaging features of 
CHC may overlap with those of hepatocellular carcinoma (HCC) and intrahepatic 
cholangiocarcinoma (ICC).
Research motivation
The contrasted-enhanced ultrasound (CEUS) Liver Imaging Reporting and Data 
System (LI-RADS) released by the American College of Radiology has been reported 
to be effective for the diagnosis of HCC. However, CHC lesions meeting the criteria for 
LR-5 classification may compromise the high specificity of LR-5 for the diagnosis of 
HCC if we only take the imaging features into consideration. Serum biomarkers, 
especially alpha-fetoprotein (AFP) and carbohydrate antigen 19-9 (CA19-9), have been 
shown to be helpful in the diagnosis of CHC. However, whether combining CEUS LI-
RADS with serum biomarkers is helpful for differentiating CHC from HCC and ICC in 
at-risk patients has not been fully evaluated.
Research objectives
The purpose of this study was to investigate whether the combination of CEUS LI-
RADS and serum biomarkers is helpful for differentiating CHC from HCC and ICC in 
patients with chronic liver disease.
Research methods
Patients with histologically confirmed CHC, ICC and HCC with chronic liver disease 
between January 2016 and December 2019 were enrolled in this retrospective case 
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control study. HCC patients were finally enrolled after one-to-two (CHC:HCC = 1:2) 
propensity score matching by tumor size, age and sex. Differences in quantitative 
variables were tested by the independent sample t-test. The rates of imaging 
characteristics were compared by using the χ2 test or Fisher’s exact test. Receiver 
operating characteristic curve analysis was used to investigate the potential of CEUS 
LI-RADS and serum tumor markers for differentiating CHC from HCC and ICC.
Research results
After propensity score matching, 134 patients (mean age of 51.4 ± 9.4 years, 108 men) 
were enrolled, including 35 CHC, 29 ICC and 70 HCC patients. Based on the CEUS LI-
RADS classification, 74.3% (26/35) and 25.7% (9/35) of CHC lesions were assessed as 
LR-M and LR-5, respectively. The rates of elevated AFP and CA19-9 levels in CHC 
patients were 51.4% and 11.4%, respectively. Simultaneous elevation of AFP and 
CA19-9 was found in 8.6% (3/35) of CHC patients. The sensitivity, specificity, positive 
predictive value (PPV), negative predictive value (NPV), accuracy and AUC of the 
aforementioned diagnostic criteria for discriminating CHC from HCC and ICC were 
40.0%, 89.9%, 58.3%, 80.9%, 76.9% and 0.649, respectively. When the reported 
prevalence rate of CHC (0.4%-14.2%) was taken into account, the PPV and NPV were 
revised to 1.6%-39.6% and 90.1%-99.7%, respectively.
Research conclusions
CHCs are more likely to be classified as LR-M than LR-5 by CEUS LI-RADS. The 
combination of the CEUS LI-RADS classification with serum tumor markers shows 
high specificity but low sensitivity for the diagnosis of CHC. Moreover, CHC could be 
confidently excluded with a high NPV.
Research perspectives
The imaging features of CHC are complicated due to its complex histopathological 
characteristics. In addition, biopsy may misguide the correct diagnosis of CHC due to 
sampling error or tissue insufficiency. This study investigated the diagnostic value of 
the CEUS LI-RADS classification combined with serological tumor markers in 
differentiating CHC from HCC and ICC. The results showed that the combined 
diagnostic criteria had high specificity and NPV but low sensitivity for the diagnosis of 
CHC. These findings could help radiologists and clinical investigators confidently 
exclude CHC lesions in the clinical setting.
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